On May 15th, the "Artificial Intelligence+Medical Health" Promotion Conference was grandly held at Xuhui Moshu Space. The launch ceremony of the first Shanghai Medical Artificial Intelligence Application Skills Competition "Zhihui Medical, AI Boundless" and the promotion ceremony of the "Data Element X" Competition Shanghai Branch Medical Health and Medical Security Track were also held at the same time on site. This event is guided by the Cyberspace Administration of the Municipal Party Committee, the Municipal Commission of Economy and Information Technology, and the Municipal Federation of Trade Unions. It is jointly organized by the Municipal Health Commission, the Municipal Data Bureau, the Municipal Medical Insurance Bureau, and the Xuhui District Government. The event gathers representatives from medical institutions, universities, and enterprises to explore the deep integration of "artificial intelligence+" and medical innovation with high-value application scenarios, and to help promote the high-quality development of the healthcare industry. Wen Daxiang, Director of the Municipal Health Commission, Cao Liqiang, Secretary of the Xuhui District Committee, and Wang Hua, Deputy Secretary and District Chief of the District Committee, attended the event.

Unveiling the List and Leading the Way to Solve Clinical Pain Points

At the event, the "Unveiling and Leading" project for the application scenarios of medical artificial intelligence in Xuhui District in 2025 was officially released, focusing on four directions: "artificial intelligence + medical services, community health, public health, and industry governance", aiming to stimulate innovation vitality from all parties and promote the precise implementation of technology. The project led by Professor Wang Lixin from the Department of Vascular Surgery at Zhongshan Hospital Affiliated to Fudan University, in collaboration with Dunwill Medical, titled "Application of Multi Modal Tandem Artificial Intelligence Model with Multi dimensional Data such as Physical Signs, Molecular Detection, and Imaging Examination in Emergency Diagnosis of Aortic Dissection", has been successfully selected!

In the emergency field, aortic dissection (AD) is one of the main causes of severe chest pain in patients admitted to the emergency department. Due to the rapid progression and high mortality rate of AD, rapid and accurate diagnosis is crucial for clinical treatment. CTA is currently the gold standard for diagnosing AD, but it cannot meet various emergency needs. In response to the difficult problem of emergency diagnosis of AD, the joint research project of Dunwill Medical and Zhongshan Hospital's vascular surgery department, the "Unveiling and Leading" project, integrates millions of data from the chest pain center, constructs an AI model for emergency diagnosis of aortic dissection, forms a fast, practical and economical ultrasound assisted diagnostic tool, significantly improves the diagnostic efficiency and accuracy of AD, and injects intelligent energy into the rescue of "golden time".

In recent years, Dunwill Medical has actively participated in the new field of artificial intelligence, exploring the application of AI in health management, clinical auxiliary diagnosis and treatment, and has achieved many fruitful results. This selection marks another authoritative recognition of the company's research and development strength and application value in the field of "Medical+AI".

During the conference, Dr. Hou Ying, Executive Director of Dunwill Medical Market & Strategic Development Center, was invited as a representative of the company to give a keynote speech on "New 'Healthy' Solutions for AI Driven Healthcare", sharing Dunwill Medical's cutting-edge exploration and innovative practices in the field of artificial intelligence healthcare. Dr. Hou Ying expressed his great honor to participate in this grand event as a representative enterprise of in vitro diagnostic reagents. Currently, the application of artificial intelligence has deeply penetrated the entire industry chain of healthcare. For diagnostic enterprises, the core dimension of AI participation in healthcare lies in predictive analysis. Through the diversity and complementarity of multimodal data fusion in artificial intelligence, precise stratification and personalized treatment of patients can be achieved, providing better solutions for precision medicine.

As a leading domestic company in the conversion of original biomarker diagnostic products, Dunwill Medical has innovatively established the miRNA7 multimodal fusion model GALADM. This model does not rely on the birth of new products, but is based on real-world practical exploration and deep mining of big data, committed to exploring the most economical and effective best clinical practice mode under the existing medical landscape. By integrating multiple clinical testing indicators and applying cutting-edge multimodal fusion algorithms for precise analysis, this model has become an excellent case of health economics in the era of artificial intelligence.

He further pointed out that immunotherapy is the foundation of future cancer treatment, and its difficulty lies in both attacking the tumor cells themselves and breaking through the complex ecosystem around the tumor - the tumor microenvironment. Dunwill Medical focuses on the construction of a digitalized pathology in vitro diagnostic product system, carries out multimodal deep learning modeling and multi omics integration analysis, and successfully establishes AI driven tumor immune microenvironment analysis, which can accurately assess the risk of recurrence. Through AI digital scanning and slicing, it is possible to clearly analyze the distribution, quantity, and spatial characteristics of tumor microenvironment cells, predict the efficacy of immunotherapy, and promote the transition from traditional pathology to intelligent digital pathology.

In addition, Professor Liu Qi's team from Tongji University, a collaborator of Dunwill Medical, successfully established a novel antigen artificial intelligence prediction model. At the same time, Dunwill Medical works closely with the Department of Hepatology at Zhongshan Hospital, using immunohistochemistry sequencing technology to accurately match tumor neoantigens with immune cell vitality, providing strong support for immunotherapy.

Finally, Dr. Hou Ying concluded that artificial intelligence is not only a technological means, but also a change in thinking. Traditional diagnostic methods rely on assumptions, which often suffer from accuracy and prediction bias issues. However, in the era of big data, by fully utilizing the power of artificial intelligence and data, we can adopt a "data-driven" thinking approach, closely rely on the rich clinical data resources of research-oriented hospitals, and deeply tap into the potential of data. This can not only help diagnostic enterprises achieve product upgrades, but also accelerate the overtaking of the domestic AI medical field and promote the entire industry to reach new heights.

This conference not only provides a high-end platform for ideological collision and technological exchange in the field of artificial intelligence, but also points out the direction for promoting the deep integration of artificial intelligence and medical innovation, and building a new paradigm of smart healthcare.

The wave of smart healthcare has arrived, and the prelude to innovative cooperation is beginning. Relying on the demonstration effect of the "unveiling and leading" project, in the future, Dunwill Medical will continue to deepen its strategic layout of "AI+Healthcare", continuously deepen the integration and innovation of artificial intelligence and medical services, inject new momentum into the digital transformation of national medical health, help Shanghai build a globally influential medical artificial intelligence innovation source and application demonstration highland, and promote the medical industry to move towards a more accurate and efficient new era!